ID E2AK1_HUMAN Reviewed; 630 AA. AC Q9BQI3; A8K2R2; Q549K6; Q8NBW3; Q9HC02; Q9NYE0; Q9P0V6; Q9P1J5; Q9P2H8; AC Q9UHG4; DT 11-JUL-2001, integrated into UniProtKB/Swiss-Prot. DT 20-JUN-2003, sequence version 2. DT 28-JAN-2026, entry version 217. DE RecName: Full=Eukaryotic translation initiation factor 2-alpha kinase 1 {ECO:0000305}; DE EC=2.7.11.1 {ECO:0000269|PubMed:32132707, ECO:0000269|PubMed:38340717}; DE AltName: Full=Heme-controlled repressor; DE Short=HCR; DE AltName: Full=Heme-regulated eukaryotic initiation factor eIF-2-alpha kinase {ECO:0000303|Ref.3}; DE AltName: Full=Heme-regulated inhibitor {ECO:0000303|PubMed:11101152}; DE Short=hHRI {ECO:0000303|PubMed:11101152}; DE AltName: Full=Hemin-sensitive initiation factor 2-alpha kinase {ECO:0000303|Ref.2}; GN Name=EIF2AK1 {ECO:0000312|HGNC:HGNC:24921}; GN Synonyms=HRI {ECO:0000303|PubMed:11101152}, GN KIAA1369 {ECO:0000303|PubMed:10718198}; ORFNames=PRO1362; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Hair follicle dermal papilla; RX PubMed=11101152; DOI=10.1007/s10059-000-0584-5; RA Hwang S.-Y., Kim M.-K., Kim J.-C.; RT "Cloning of hHRI, human heme-regulated eukaryotic initiation factor 2alpha RT kinase: down-regulated in epithelial ovarian cancers."; RL Mol. Cells 10:584-591(2000). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RA Tu Q., Yu L., Hu P.R., Fu Q., Cui Y.Y., Zhao S.Y.; RT "Cloning and sequencing of a novel human cDNA homologous to rat hemin- RT sensitive initiation factor 2a kinase mRNA."; RL Submitted (OCT-1998) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Skin; RA Cannon G., Naik S.M., Boss J.M., Caughman S.W.; RT "Cloning of the human heme-regulated eukaryotic initiation factor 2-alpha RT kinase from TNF-alpha stimulated dermal microvascular endothelial cells."; RL Submitted (AUG-1999) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=10718198; DOI=10.1093/dnares/7.1.65; RA Nagase T., Kikuno R., Ishikawa K., Hirosawa M., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XVI. The RT complete sequences of 150 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 7:65-73(2000). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Hypothalamus; RX PubMed=10931946; DOI=10.1073/pnas.160270997; RA Hu R.-M., Han Z.-G., Song H.-D., Peng Y.-D., Huang Q.-H., Ren S.-X., RA Gu Y.-J., Huang C.-H., Li Y.-B., Jiang C.-L., Fu G., Zhang Q.-H., Gu B.-W., RA Dai M., Mao Y.-F., Gao G.-F., Rong R., Ye M., Zhou J., Xu S.-H., Gu J., RA Shi J.-X., Jin W.-R., Zhang C.-K., Wu T.-M., Huang G.-Y., Chen Z., RA Chen M.-D., Chen J.-L.; RT "Gene expression profiling in the human hypothalamus-pituitary-adrenal axis RT and full-length cDNA cloning."; RL Proc. Natl. Acad. Sci. U.S.A. 97:9543-9548(2000). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Amygdala; RX PubMed=11230166; DOI=10.1101/gr.gr1547r; RA Wiemann S., Weil B., Wellenreuther R., Gassenhuber J., Glassl S., RA Ansorge W., Boecher M., Bloecker H., Bauersachs S., Blum H., Lauber J., RA Duesterhoeft A., Beyer A., Koehrer K., Strack N., Mewes H.-W., RA Ottenwaelder B., Obermaier B., Tampe J., Heubner D., Wambutt R., Korn B., RA Klein M., Poustka A.; RT "Towards a catalog of human genes and proteins: sequencing and analysis of RT 500 novel complete protein coding human cDNAs."; RL Genome Res. 11:422-435(2001). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RC TISSUE=Bone marrow; RX PubMed=12391722; DOI=10.1080/10425170290023428; RA Omasa T., Chen Y.-G., Mantalaris A., Tsai Y.C., Wu J.H.; RT "Molecular cloning and sequencing of the human heme-regulated eukaryotic RT initiation factor 2 alpha (eIF-2 alpha) kinase from bone marrow culture."; RL DNA Seq. 13:133-137(2002). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ARG-558. RC TISSUE=Placenta, and Tongue; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Amygdala; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12690205; DOI=10.1126/science.1083423; RA Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K., RA Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R., RA Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A., RA Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D., RA Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S., RA Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R., RA Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N., RA Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E., RA Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R., RA Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T., RA Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W., RA Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A., RA Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X., RA Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E., RA Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H., RA Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J., RA Adams M.D., Tsui L.-C.; RT "Human chromosome 7: DNA sequence and biology."; RL Science 300:767-772(2003). RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [12] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Ovary; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [13] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 450-630, AND VARIANT ARG-558. RC TISSUE=Fetal liver; RA Zhang C., Yu Y., Zhang S., Wei H., Zhou G., Ouyang S., Luo L., Bi J., RA Liu M., He F.; RT "Functional prediction of the coding sequences of 121 new genes deduced by RT analysis of cDNA clones from human fetal liver."; RL Submitted (DEC-1998) to the EMBL/GenBank/DDBJ databases. RN [14] RP INTERACTION WITH CDC37 AND THE HSP90 COMPLEX. RX PubMed=11036079; DOI=10.1074/jbc.m007583200; RA Shao J., Grammatikakis N., Scroggins B.T., Uma S., Huang W., Chen J.-J., RA Hartson S.D., Matts R.L.; RT "Hsp90 regulates p50(cdc37) function during the biogenesis of the active RT conformation of the heme-regulated eIF2 alpha kinase."; RL J. Biol. Chem. 276:206-214(2001). RN [15] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [16] RP RETRACTED PAPER. RX PubMed=20071449; DOI=10.1124/mol.109.061259; RA Acharya P., Chen J.J., Correia M.A.; RT "Hepatic heme-regulated inhibitor (HRI) eukaryotic initiation factor 2alpha RT kinase: a protagonist of heme-mediated translational control of CYP2B RT enzymes and a modulator of basal endoplasmic reticulum stress tone."; RL Mol. Pharmacol. 77:575-592(2010). RN [17] RP RETRACTION NOTICE OF PUBMED:20071449. RX PubMed=34404736; DOI=10.1124/mol.109.061259retraction; RA Acharya P., Chen J.J., Correia M.A.; RT "Notice of Retraction: Acharya P, Chen J-J, Correia MA (2010) Hepatic heme- RT regulated inhibitor (HRI) eukaryotic initiation factor 2alpha kinase: a RT protagonist of heme-mediated translational control of CYP2B enzymes and a RT modulator of basal endoplasmic reticulum stress tone. Mol Pharmacol RT 77(4):575-592; doi:10.1124/mol.109.061259."; RL Mol. Pharmacol. 100:65-65(2021). RN [18] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [19] RP INVOLVEMENT IN LEMSPAD, FUNCTION, VARIANT LEMSPAD VAL-448, AND RP CHARACTERIZATION OF VARIANT LEMSPAD VAL-448. RX PubMed=32197074; DOI=10.1016/j.ajhg.2020.02.016; RG Undiagnosed Diseases Network; RA Mao D., Reuter C.M., Ruzhnikov M.R.Z., Beck A.E., Farrow E.G., Emrick L.T., RA Rosenfeld J.A., Mackenzie K.M., Robak L., Wheeler M.T., Burrage L.C., RA Jain M., Liu P., Calame D., Kuery S., Sillesen M., Schmitz-Abe K., RA Tonduti D., Spaccini L., Iascone M., Genetti C.A., Koenig M.K., Graf M., RA Tran A., Alejandro M., Lee B.H., Thiffault I., Agrawal P.B., RA Bernstein J.A., Bellen H.J., Chao H.T.; RT "De novo EIF2AK1 and EIF2AK2 variants are associated with developmental RT delay, leukoencephalopathy, and neurologic decompensation."; RL Am. J. Hum. Genet. 106:570-583(2020). RN [20] RP FUNCTION, ACTIVITY REGULATION, AND INTERACTION WITH DELE1. RX PubMed=32132706; DOI=10.1038/s41586-020-2076-4; RA Fessler E., Eckl E.M., Schmitt S., Mancilla I.A., Meyer-Bender M.F., RA Hanf M., Philippou-Massier J., Krebs S., Zischka H., Jae L.T.; RT "A pathway coordinated by DELE1 relays mitochondrial stress to the RT cytosol."; RL Nature 579:433-437(2020). RN [21] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND INTERACTION WITH RP DELE1. RX PubMed=32132707; DOI=10.1038/s41586-020-2078-2; RA Guo X., Aviles G., Liu Y., Tian R., Unger B.A., Lin Y.T., Wiita A.P., RA Xu K., Correia M.A., Kampmann M.; RT "Mitochondrial stress is relayed to the cytosol by an OMA1-DELE1-HRI RT pathway."; RL Nature 579:427-432(2020). RN [22] RP FUNCTION, ACTIVITY REGULATION, AND INTERACTION WITH DELE1. RX PubMed=37327776; DOI=10.1016/j.molcel.2023.05.031; RA Sekine Y., Houston R., Eckl E.M., Fessler E., Narendra D.P., Jae L.T., RA Sekine S.; RT "A mitochondrial iron-responsive pathway regulated by DELE1."; RL Mol. Cell 83:2059-2076(2023). RN [23] RP FUNCTION, ACTIVITY REGULATION, AND INTERACTION WITH DELE1. RX PubMed=37550454; DOI=10.1038/s41594-023-01061-0; RA Yang J., Baron K.R., Pride D.E., Schneemann A., Guo X., Chen W., Song A.S., RA Aviles G., Kampmann M., Wiseman R.L., Lander G.C.; RT "DELE1 oligomerization promotes integrated stress response activation."; RL Nat. Struct. Mol. Biol. 30:1295-1302(2023). RN [24] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND INTERACTION WITH RP DELE1. RX PubMed=38340717; DOI=10.1016/j.molcel.2024.01.016; RA Chakrabarty Y., Yang Z., Chen H., Chan D.C.; RT "The HRI branch of the integrated stress response selectively triggers RT mitophagy."; RL Mol. Cell 84:1090-1100(2024). RN [25] RP UBIQUITINATION. RX PubMed=38297121; DOI=10.1038/s41586-023-06985-7; RA Haakonsen D.L., Heider M., Ingersoll A.J., Vodehnal K., Witus S.R., RA Uenaka T., Wernig M., Rape M.; RT "Stress response silencing by an E3 ligase mutated in neurodegeneration."; RL Nature 626:874-880(2024). RN [26] RP VARIANTS [LARGE SCALE ANALYSIS] THR-117; THR-132; LYS-134; SER-139; RP HIS-145; SER-202; LEU-292; HIS-319 AND ARG-558. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [27] RP VARIANT ARG-558. RX PubMed=28501589; DOI=10.1016/j.clim.2017.05.009; RA Sadovnick A.D., Traboulsee A.L., Zhao Y., Bernales C.Q., Encarnacion M., RA Ross J.P., Yee I.M., Criscuoli M.G., Vilarino-Gueell C.; RT "Genetic modifiers of multiple sclerosis progression, severity and onset."; RL Clin. Immunol. 180:100-105(2017). CC -!- FUNCTION: Metabolic-stress sensing protein kinase that phosphorylates CC the alpha subunit of eukaryotic translation initiation factor 2 CC (EIF2S1/eIF-2-alpha) in response to various stress conditions CC (PubMed:32132706, PubMed:32132707, PubMed:37327776, PubMed:37550454, CC PubMed:38340717). Key activator of the integrated stress response (ISR) CC required for adaptation to various stress, such as heme deficiency, CC oxidative stress, osmotic shock, mitochondrial dysfunction and heat CC shock (PubMed:32132706, PubMed:32132707, PubMed:37327776, CC PubMed:37550454, PubMed:38340717). EIF2S1/eIF-2-alpha phosphorylation CC in response to stress converts EIF2S1/eIF-2-alpha in a global protein CC synthesis inhibitor, leading to a global attenuation of cap-dependent CC translation, while concomitantly initiating the preferential CC translation of ISR-specific mRNAs, such as the transcriptional CC activator ATF4, and hence allowing ATF4-mediated reprogramming CC (PubMed:32132706, PubMed:32132707, PubMed:37327776). Acts as a key CC sensor of heme-deficiency: in normal conditions, binds hemin via a CC cysteine thiolate and histidine nitrogenous coordination, leading to CC inhibit the protein kinase activity (By similarity). This binding CC occurs with moderate affinity, allowing it to sense the heme CC concentration within the cell: heme depletion relieves inhibition and CC stimulates kinase activity, activating the ISR (By similarity). Thanks CC to this unique heme-sensing capacity, plays a crucial role to shut off CC protein synthesis during acute heme-deficient conditions (By CC similarity). In red blood cells (RBCs), controls hemoglobin synthesis CC ensuring a coordinated regulation of the synthesis of its heme and CC globin moieties (By similarity). It thereby plays an essential CC protective role for RBC survival in anemias of iron deficiency (By CC similarity). Iron deficiency also triggers activation by full-length CC DELE1 (PubMed:37327776). Also activates the ISR in response to CC mitochondrial dysfunction: HRI/EIF2AK1 protein kinase activity is CC activated upon binding to the processed form of DELE1 (S-DELE1), CC thereby promoting the ATF4-mediated reprogramming (PubMed:32132706, CC PubMed:32132707). Also acts as an activator of mitophagy in response to CC mitochondrial damage: catalyzes phosphorylation of eIF-2-alpha (EIF2S1) CC following activation by S-DELE1, thereby promoting mitochondrial CC localization of EIF2S1, triggering PRKN-independent mitophagy CC (PubMed:38340717). {ECO:0000250|UniProtKB:Q9Z2R9, CC ECO:0000269|PubMed:32132706, ECO:0000269|PubMed:32132707, CC ECO:0000269|PubMed:32197074, ECO:0000269|PubMed:37550454, CC ECO:0000269|PubMed:38340717}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:32132707, ECO:0000269|PubMed:38340717}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990; CC Evidence={ECO:0000269|PubMed:32132707, ECO:0000269|PubMed:38340717}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000250|UniProtKB:Q9Z2R9}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46609; CC Evidence={ECO:0000250|UniProtKB:Q9Z2R9}; CC -!- ACTIVITY REGULATION: In normal conditions, the protein kinase activity CC is inhibited; inhibition is relieved by various stress conditions (By CC similarity). Inhibited by heme: in presence of heme, forms a disulfide- CC linked inactive homodimer (By similarity). Heme depletion relieves CC inhibition and stimulates kinase activity by autophosphorylation. CC Inhibited by the heme metabolites biliverdin and bilirubin (By CC similarity). Induced by oxidative stress generated by arsenite CC treatment. Binding of nitric oxide (NO) to the heme iron in the N- CC terminal heme-binding domain activates the kinase activity, while CC binding of carbon monoxide (CO) suppresses kinase activity (By CC similarity). Protein kinase activity is also activated upon binding to CC DELE1 in response to various stress, triggering the integrated stress CC response (ISR): activated by full-length DELE1 in response to iron CC deficiency, while it is activated by the processed form of DELE1 (S- CC DELE1) in response to mitochondrial stress (PubMed:32132706, CC PubMed:32132707, PubMed:37327776, PubMed:37550454, PubMed:38340717). CC {ECO:0000250|UniProtKB:P33279, ECO:0000250|UniProtKB:Q9Z2R9, CC ECO:0000269|PubMed:32132706, ECO:0000269|PubMed:32132707, CC ECO:0000269|PubMed:37327776, ECO:0000269|PubMed:37550454, CC ECO:0000269|PubMed:38340717}. CC -!- SUBUNIT: Synthesized in an inactive form that binds to the N-terminal CC domain of CDC37 (PubMed:11036079). Has to be associated with a CC multiprotein complex containing Hsp90, CDC37 and PPP5C for maturation CC and activation by autophosphorylation (PubMed:11036079). The CC phosphatase PPP5C modulates this activation (PubMed:11036079). CC Homodimer; homodimerizes in presence of heme, forming a disulfide- CC linked inactive homodimer (By similarity). Interacts with DELE1; binds CC both to full-length DELE1 and processed form of DELE1 (S-DELE1) in CC response to stress, leading to activate its protein kinase activity and CC trigger the integrated stress response (ISR) (PubMed:32132706, CC PubMed:32132707, PubMed:37327776, PubMed:37550454, PubMed:38340717). CC {ECO:0000250|UniProtKB:P33279, ECO:0000269|PubMed:11036079, CC ECO:0000269|PubMed:32132706, ECO:0000269|PubMed:32132707, CC ECO:0000269|PubMed:37327776, ECO:0000269|PubMed:37550454, CC ECO:0000269|PubMed:38340717}. CC -!- INTERACTION: CC Q9BQI3; P08238: HSP90AB1; NbExp=2; IntAct=EBI-640377, EBI-352572; CC Q9BQI3; P11142: HSPA8; NbExp=2; IntAct=EBI-640377, EBI-351896; CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q9BQI3-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9BQI3-2; Sequence=VSP_007589; CC -!- PTM: Activated by autophosphorylation; phosphorylated predominantly on CC serine and threonine residues, but also on tyrosine residues. CC Autophosphorylation at Thr-488 is required for kinase activation. The CC active autophosphorylated form apparently is largely refractory to CC cellular heme fluctuations. {ECO:0000250|UniProtKB:Q9Z2R9}. CC -!- PTM: Ubiquitinated and degraded by the SIFI complex once the CC mitochondrial stress has been resolved, thereby providing stress CC response silencing (PubMed:38297121). Within the SIFI complex, UBR4 CC initiates ubiquitin chain that are further elongated or branched by CC KCMF1 (PubMed:38297121). {ECO:0000269|PubMed:38297121}. CC -!- DISEASE: Leukoencephalopathy, motor delay, spasticity, and dysarthria CC syndrome (LEMSPAD) [MIM:618878]: A disorder characterized by delayed CC motor development, speech delay with dysarthria, hypertonia, CC progressive spasticity, hyperreflexia, and bradykinesia. Cognition is CC normal. Patients manifest anxiety and attention deficit-hyperactivity CC disorder. {ECO:0000269|PubMed:32197074}. Note=The disease may be caused CC by variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. GCN2 subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- CAUTION: Was reported to be expressed predominantly in erythroid cells CC and at much lower levels in hepatocytes. However, this paper has been CC retracted because there was improper manipulation, reuse and analyses. CC {ECO:0000305|PubMed:20071449, ECO:0000305|PubMed:34404736}. CC -!- SEQUENCE CAUTION: CC Sequence=AAF70289.1; Type=Frameshift; Evidence={ECO:0000305}; CC Sequence=AAF71057.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAA92607.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF255050; AAF70289.1; ALT_FRAME; mRNA. DR EMBL; AF100784; AAP97223.1; -; mRNA. DR EMBL; AF181071; AAF18391.1; -; mRNA. DR EMBL; AB037790; BAA92607.1; ALT_INIT; mRNA. DR EMBL; AF183414; AAG09683.1; -; mRNA. DR EMBL; AL136563; CAB66498.1; -; mRNA. DR EMBL; AF147094; AAF66736.1; -; mRNA. DR EMBL; AK075192; BAC11461.1; -; mRNA. DR EMBL; AK290327; BAF83016.1; -; mRNA. DR EMBL; AL834494; CAD39152.1; -; mRNA. DR EMBL; CH236963; EAL23714.1; -; Genomic_DNA. DR EMBL; CH878731; EAW55049.1; -; Genomic_DNA. DR EMBL; BC006524; AAH06524.1; -; mRNA. DR EMBL; AF116634; AAF71057.1; ALT_INIT; mRNA. DR CCDS; CCDS5345.1; -. [Q9BQI3-1] DR RefSeq; NP_001127807.1; NM_001134335.2. [Q9BQI3-2] DR RefSeq; NP_055228.2; NM_014413.3. [Q9BQI3-1] DR AlphaFoldDB; Q9BQI3; -. DR SMR; Q9BQI3; -. DR BioGRID; 118002; 31. DR FunCoup; Q9BQI3; 1893. DR IntAct; Q9BQI3; 28. DR STRING; 9606.ENSP00000199389; -. DR BindingDB; Q9BQI3; -. DR ChEMBL; CHEMBL6029; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q9BQI3; -. DR GuidetoPHARMACOLOGY; 2015; -. DR iPTMnet; Q9BQI3; -. DR PhosphoSitePlus; Q9BQI3; -. DR BioMuta; EIF2AK1; -. DR DMDM; 32172458; -. DR CPTAC; CPTAC-3035; -. DR jPOST; Q9BQI3; -. DR MassIVE; Q9BQI3; -. DR PaxDb; 9606-ENSP00000199389; -. DR PeptideAtlas; Q9BQI3; -. DR ProteomicsDB; 78682; -. [Q9BQI3-1] DR ProteomicsDB; 78683; -. [Q9BQI3-2] DR Pumba; Q9BQI3; -. DR Antibodypedia; 11579; 315 antibodies from 30 providers. DR DNASU; 27102; -. DR Ensembl; ENST00000199389.11; ENSP00000199389.6; ENSG00000086232.14. [Q9BQI3-1] DR GeneID; 27102; -. DR KEGG; hsa:27102; -. DR MANE-Select; ENST00000199389.11; ENSP00000199389.6; NM_014413.4; NP_055228.2. DR UCSC; uc003spp.4; human. [Q9BQI3-1] DR AGR; HGNC:24921; -. DR ClinPGx; PA134919097; -. DR CTD; 27102; -. DR DisGeNET; 27102; -. DR GeneCards; EIF2AK1; -. DR HGNC; HGNC:24921; EIF2AK1. DR HPA; ENSG00000086232; Low tissue specificity. DR MalaCards; EIF2AK1; -. DR MIM; 613635; gene. DR MIM; 618878; phenotype. DR OpenTargets; ENSG00000086232; -. DR VEuPathDB; HostDB:ENSG00000086232; -. DR eggNOG; KOG1035; Eukaryota. DR GeneTree; ENSGT00940000157605; -. DR HOGENOM; CLU_000288_134_1_1; -. DR InParanoid; Q9BQI3; -. DR OMA; WDWIADR; -. DR OrthoDB; 1405469at2759; -. DR PAN-GO; Q9BQI3; 1 GO annotation based on evolutionary models. DR PhylomeDB; Q9BQI3; -. DR PathwayCommons; Q9BQI3; -. DR Reactome; R-HSA-9648895; Response of EIF2AK1 (HRI) to heme deficiency. DR Reactome; R-HSA-9840373; Cellular response to mitochondrial stress. DR SignaLink; Q9BQI3; -. DR SIGNOR; Q9BQI3; -. DR Agora; ENSG00000086232; -. DR BioGRID-ORCS; 27102; 21 hits in 1192 CRISPR screens. DR CD-CODE; DEE660B4; Stress granule. DR ChiTaRS; EIF2AK1; human. DR GeneWiki; EIF2AK1; -. DR GenomeRNAi; 27102; -. DR Pharos; Q9BQI3; Tchem. DR PRO; PR:Q9BQI3; -. DR Proteomes; UP000005640; Chromosome 7. DR RNAct; Q9BQI3; protein. DR Bgee; ENSG00000086232; Expressed in trabecular bone tissue and 200 other cell types or tissues. DR ExpressionAtlas; Q9BQI3; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; IDA:UniProt. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004694; F:eukaryotic translation initiation factor 2alpha kinase activity; IDA:UniProtKB. DR GO; GO:0020037; F:heme binding; ISS:UniProtKB. DR GO; GO:0042803; F:protein homodimerization activity; ISS:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0002526; P:acute inflammatory response; IEA:Ensembl. DR GO; GO:0051649; P:establishment of localization in cell; IEA:Ensembl. DR GO; GO:0140468; P:HRI-mediated signaling; IDA:UniProtKB. DR GO; GO:0140467; P:integrated stress response signaling; IDA:UniProtKB. DR GO; GO:0030225; P:macrophage differentiation; IEA:Ensembl. DR GO; GO:0060586; P:multicellular organismal-level iron ion homeostasis; IEA:Ensembl. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IEA:Ensembl. DR GO; GO:0046986; P:negative regulation of hemoglobin biosynthetic process; ISS:UniProtKB. DR GO; GO:0045993; P:negative regulation of translational initiation by iron; NAS:UniProtKB. DR GO; GO:0006909; P:phagocytosis; IEA:Ensembl. DR GO; GO:1901526; P:positive regulation of mitophagy; IDA:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; ISS:UniProtKB. DR GO; GO:0070585; P:protein localization to mitochondrion; IDA:UniProt. DR GO; GO:0046501; P:protoporphyrinogen IX metabolic process; IEA:Ensembl. DR GO; GO:0006446; P:regulation of translational initiation; IBA:GO_Central. DR GO; GO:1990641; P:response to iron ion starvation; IDA:UniProtKB. DR CDD; cd14049; STKc_EIF2AK1_HRI; 1. DR FunFam; 3.30.200.20:FF:000380; Eukaryotic translation initiation factor 2 alpha kinase 1; 1. DR FunFam; 1.10.510.10:FF:000375; Putative eukaryotic translation initiation factor 2-alpha kinase 1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR050339; CC_SR_Kinase. DR InterPro; IPR054521; HRI2_3H. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR11042:SF160; EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 1; 1. DR PANTHER; PTHR11042; EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE EIF2-ALPHA KINASE -RELATED; 1. DR Pfam; PF22949; HRI2_3H; 1. DR Pfam; PF00069; Pkinase; 2. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW Alternative splicing; ATP-binding; Disulfide bond; Kinase; KW Nucleotide-binding; Phosphoprotein; Protein synthesis inhibitor; KW Proteomics identification; Reference proteome; Repeat; KW Serine/threonine-protein kinase; Transferase; Ubl conjugation. FT CHAIN 1..630 FT /note="Eukaryotic translation initiation factor 2-alpha FT kinase 1" FT /id="PRO_0000085941" FT DOMAIN 167..583 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REPEAT 410..415 FT /note="HRM 1" FT REPEAT 552..557 FT /note="HRM 2" FT REGION 1..40 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 259..301 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 85..104 FT /note="SIFI-degron" FT /evidence="ECO:0000269|PubMed:38297121" FT COMPBIAS 285..294 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 442 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 173..181 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 196 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT SITE 80 FT /note="Heme-binding" FT /evidence="ECO:0000250|UniProtKB:P33279" FT MOD_RES 285 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q63185" FT MOD_RES 486 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:Q9Z2R9" FT MOD_RES 488 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:Q9Z2R9" FT MOD_RES 493 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q9Z2R9" FT VAR_SEQ 244 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:11230166, FT ECO:0000303|PubMed:12391722, ECO:0000303|PubMed:17974005" FT /id="VSP_007589" FT VARIANT 117 FT /note="R -> T (in dbSNP:rs34889754)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040466" FT VARIANT 132 FT /note="K -> T (in dbSNP:rs34851195)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040467" FT VARIANT 134 FT /note="R -> K (in dbSNP:rs55744865)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040468" FT VARIANT 139 FT /note="P -> S (in dbSNP:rs55963745)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040469" FT VARIANT 145 FT /note="R -> H (in dbSNP:rs55971369)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040470" FT VARIANT 202 FT /note="G -> S (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs1216460058)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040471" FT VARIANT 292 FT /note="F -> L (in dbSNP:rs55982710)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040472" FT VARIANT 319 FT /note="L -> H (in dbSNP:rs34909691)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040473" FT VARIANT 448 FT /note="I -> V (in LEMSPAD; uncertain significance; mildly FT reduced phosphorylation of eukaryotic translation FT initiation factor 2-alpha; dbSNP:rs1583476115)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084259" FT VARIANT 558 FT /note="K -> R (in dbSNP:rs2640)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:28501589, FT ECO:0000269|Ref.13" FT /id="VAR_015732" FT CONFLICT 2 FT /note="Q -> L (in Ref. 3; AAF18391)" FT /evidence="ECO:0000305" FT CONFLICT 4 FT /note="G -> D (in Ref. 8; BAF83016)" FT /evidence="ECO:0000305" FT CONFLICT 24..32 FT /note="PPAIDFPAE -> RRHRLSRR (in Ref. 1; AAF70289)" FT /evidence="ECO:0000305" FT CONFLICT 137 FT /note="Q -> R (in Ref. 1; AAF70289)" FT /evidence="ECO:0000305" FT CONFLICT 149 FT /note="I -> T (in Ref. 8; BAF83016)" FT /evidence="ECO:0000305" FT CONFLICT 171 FT /note="A -> V (in Ref. 3; AAF18391)" FT /evidence="ECO:0000305" FT CONFLICT 206 FT /note="T -> P (in Ref. 7; AAF66736)" FT /evidence="ECO:0000305" SQ SEQUENCE 630 AA; 71106 MW; D63021651806620B CRC64; MQGGNSGVRK REEEGDGAGA VAAPPAIDFP AEGPDPEYDE SDVPAEIQVL KEPLQQPTFP FAVANQLLLV SLLEHLSHVH EPNPLRSRQV FKLLCQTFIK MGLLSSFTCS DEFSSLRLHH NRAITHLMRS AKERVRQDPC EDISRIQKIR SREVALEAQT SRYLNEFEEL AILGKGGYGR VYKVRNKLDG QYYAIKKILI KGATKTVCMK VLREVKVLAG LQHPNIVGYH TAWIEHVHVI QPRADRAAIE LPSLEVLSDQ EEDREQCGVK NDESSSSSII FAEPTPEKEK RFGESDTENQ NNKSVKYTTN LVIRESGELE STLELQENGL AGLSASSIVE QQLPLRRNSH LEESFTSTEE SSEENVNFLG QTEAQYHLML HIQMQLCELS LWDWIVERNK RGREYVDESA CPYVMANVAT KIFQELVEGV FYIHNMGIVH RDLKPRNIFL HGPDQQVKIG DFGLACTDIL QKNTDWTNRN GKRTPTHTSR VGTCLYASPE QLEGSEYDAK SDMYSLGVVL LELFQPFGTE MERAEVLTGL RTGQLPESLR KRCPVQAKYI QHLTRRNSSQ RPSAIQLLQS ELFQNSGNVN LTLQMKIIEQ EKEIAELKKQ LNLLSQDKGV RDDGKDGGVG //